Finanzen von Century Therapeutics Inc (IPSC)IPSCCentury Therapeutics Inc

Evaluating the bottom line, Century Therapeutics, Inc. maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -49.65%, provide a clear picture of how effectively IPSC converts its operational activities into shareholder value.

In the context of the broader market, IPSC competes directly with industry leaders such as UPB and ZNTL. With a market capitalization of $403.80M, it holds a leading position in the sector. When comparing efficiency, IPSC's gross margin of N/A stands against UPB's N/A and ZNTL's N/A. Such benchmarking helps identify whether Century Therapeutics, Inc. is trading at a premium or discount relative to its financial performance.

Century Therapeutics has shown substantial revenue growth, reporting $109.2 million in Q1 2025, but continues to operate at a loss with a net income of -$21.6 million in Q1 2026. The gross margin remains strong at 100% for previous quarters, but recent quarters show a decline in profitability.